Kidney cancer | Bladder cancer | Prostate cancer | |||||
---|---|---|---|---|---|---|---|
Both | Male | Female | Both | Male | Female | Male | |
1990* | |||||||
Incident cases (× 103) | 145.91 (140.80–150.33) | 86.06 (82.70–89.44) | 59.85 (57.39–62.13) | 234.75 (225.46–243.08) | 177.76 (170.77–184.13) | 56.99 (53.45–60.31) | 524.11 (409.13–613.01) |
Deaths (× 103) | 72.10 (68.88–74.67) | 43.46 (41.33–45.51) | 28.64 (27.24–29.66) | 121.50 (114.75–127.17) | 88.12 (83.47–91.86) | 33.38 (30.66–35.84) | 233.00 (191.40–268.88) |
DALYs (× 103) | 2039.40 (1943.70–2144.10) | 1260.71 (1189.84–1349.99) | 778.69 (738.21–829.72) | 2567.06 (2429.47–2691.11) | 1901.45 (1798.60–1987.27) | 665.60 (613.69–722.30) | 4360.51 (3528.03–4951.01) |
ASIR (1/105) | 3.53 (3.40–3.63) | 4.51 (4.34–4.67) | 2.70 (2.59–2.80) | 6.27 (5.98–6.50) | 10.94 (10.43–11.34) | 2.77 (2.59–2.93) | 34.13 (26.83–39.65) |
ASMR (1/105) | 1.86 (1.77–1.93) | 2.50 (2.37–2.60) | 1.36 (1.28–1.41) | 3.49 (3.27–3.66) | 6.13 (5.77–6.41) | 1.70 (1.54–1.82) | 18.13 (14.68–21.19) |
ASDR (1/105) | 47.28 (45.22–49.37) | 61.96 (58.81–65.46) | 34.30 (32.65–36.08) | 66.59 (63.00–69.73) | 111.68 (105.56–116.61) | 31.66 (29.19–34.29) | 286.30 (232.78–326.21) |
2019* | |||||||
Incident cases (× 103) | 371.75 (344.59–402.35) | 240.54 (220.79–261.82) | 131.21 (119.71–142.42) | 524.30 (475.95–569.43) | 407.87 (371.30–443.75) | 116.44 (103.71–128.21) | 1410.45 (1227.90–1825.77) |
Deaths (× 103) | 166.44 (155.46–176.3) | 108.77 (101.48–115.82) | 57.67 (52.24–61.90) | 228.73 (210.74–243.19) | 169.21 (156.92–180.66) | 59.53 (52.33–64.58) | 486.84 (420.5–593.69) |
DALYs (× 103) | 4052.82 (3801.04–4317.49) | 2735.71 (2544.82–2931.33) | 1317.11 (1228.35–1413.53) | 4392.58 (4090.44–4702.73) | 3326.50 (3093.91–3570.17) | 1066.08 (962.71–1150.12) | 8644.87 (7548.02–10,559.87) |
ASIR (1/105) | 4.55 (4.22–4.93) | 6.24 (5.74–6.79) | 3.07 (2.80–3.33) | 6.52 (5.93–7.09) | 11.28 (10.23–12.27) | 2.66 (2.37–2.93) | 38.63 (33.63–49.83) |
ASMR (1/105) | 2.08 (1.93–2.20) | 2.99 (2.78–3.18) | 1.33 (1.20–1.42) | 2.94 (2.70–3.13) | 5.09 (4.69–5.44) | 1.36 (1.19–1.47) | 15.28 (13.00–18.57) |
ASDR (1/105) | 49.62 (46.46–52.94) | 70.06 (65.14–75.07) | 31.08 (28.95–33.38) | 54.20 (50.35–57.97) | 90.17 (83.63–96.61) | 24.43 (22.10–26.35) | 244.07 (211.78–297.72) |
1990–2019 | |||||||
ASIR | |||||||
EAPC (95% CI) | 0.87 (0.76–0.99) | 1.13 (1.01–1.26) | 0.39 (0.30–0.49) | 0.07 (0.04–0.10) | 0.06 (0.03–0.08) | − 0.24 (− 0.29 to − 0.18) | 0.26 (0.15–0.37) |
ASMR | |||||||
EAPC (95% CI) | 0.35 (0.26–0.45) | 0.61 (0.51–0.70) | − 0.13 (− 0.20 to − 0.05) | − 0.68 (− 0.71 to − 0.65) | − 0.71 (− 0.73 to − 0.68) | − 0.89 (− 0.94 to − 0.84) | − 0.75 (− 0.84 to − 0.67) |
ASDR | |||||||
EAPC (95% CI) | 0.12 (0.04–0.20) | 0.40 (0.30–0.49) | − 0.41 (− 0.46 to − 0.36) | − 0.83 (− 0.86 to − 0.79) | − 0.84 (− 0.87 to − 0.81) | − 1.04 (− 1.08 to − 0.99) | − 0.71 (− 0.78 to − 0.64) |